GENFIT and EVerZom have initiated a research collaboration to explore EViv, an innovative exosome-based regenerative therapy for Acute-On-Chronic Liver Failure (ACLF), with plans to conduct exploratory studies and potentially advance into clinical development within 18 months.

After losing some value lately, a hammer chart pattern has been formed for GENFIT S.A. Unsponsored ADR (GNFT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

HC Wainwright has upgraded Intercept Pharmaceuticals Inc (NASDAQ: ICPT) to Buy from Sell, with a price target of $19, up from $8. In June, Intercept's obeticholic acid (OCA) in NASH received a second CRL, prompting the company to discontinue the NASH program entirely.  The move involved restructuring but positions the company to be profitab...

It's time to look ahead to a new quarter and final half of the year. Piper Sandler offers some stock ideas to sell and buy.

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.